Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Breast 1

Conditions

Stomach Neoplasms 12Colorectal Neoplasms 10Adenocarcinoma 6Breast Neoplasms 5Pancreatic Neoplasms 4Neoplasm Metastasis 4Esophageal Neoplasms 4Sarcoma 2Salivary Gland Neoplasms 2Prostatic Neoplasms 2Ovarian Neoplasms 2Neoplasms 2Melanoma 2HER2-positive Gastric Cancer 2Gastrointestinal Neoplasms 2Endometrial Neoplasms 2Colonic Neoplasms 2Carcinoma, Renal Cell 2Adenocarcinoma Of Esophagus 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Thyroid Neoplasms 1Testicular Neoplasms 1Small Cell Lung Carcinoma 1Rectal Neoplasms 1Neoplasm, Residual 1Mouth Neoplasms 1

Interventions

Fluorouracil 67Radiotherapy 53Cisplatin 52Oxaliplatin 47Leucovorin 37Paclitaxel 36Irinotecan 27Docetaxel 23Capecitabine 20Nivolumab 17Carboplatin 16pembrolizumab 15Radiation 15Neoadjuvant Therapy 15Surgical Procedures, Operative 12Cetuximab 12durvalumab 9Drug Therapy 9Biopsy 9Taxes 8Folfox protocol 8Chemotherapy, Adjuvant 8Trastuzumab 7Magnetic Resonance Spectroscopy 7Gefitinib 7Endoscopy 7tremelimumab 6Specimen Handling 6Endoscopy, Digestive System 6Ramucirumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Adenocarcinoma Of Esophagus × trastuzumab deruxtecan × Gastrointestinal × Clear all
NCT06324357 2026-05-26

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

Boehringer Ingelheim

Phase 1/2 Recruiting
768 enrolled
BreastGastrointestinal

Adenocarcinoma Of Esophagus, Breast Neoplasms, Colorectal Neoplasms

NCT05480384 2026-04-21

Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction

Brown University

Phase 2 Active not recruiting
1 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡